MedTrace Logo

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

NCT03965208 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2019-05-28

No results posted yet for this study

Summary

This study will evaluate heparin as compared to bivalirudin for systemic anticoagulation in adult patients that require extracorporeal membrane oxygenation (ECMO). Half of the participants will receive heparin and half will receive bivalirudin.

Conditions

  • Extracorporeal Membrane Oxygenation Complication
  • Anticoagulants

Interventions

DRUG

Bivalirudin

titrated continuous infusion

DRUG

Unfractionated heparin

titrated continuous infusion

Sponsors & Collaborators

  • Pacific University

    collaborator OTHER

  • Legacy Health System

    lead OTHER

Principal Investigators

  • R Brigg Turner, PharmD · Pacific University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-23
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03965208 on ClinicalTrials.gov